Navigation Links
Pivotal Phase 3 Data from Boehringer Ingelheim Hepatitis C Portfolio to be Presented at 64th Annual AASLD Meeting
Date:10/1/2013

the combination in treatment-naive, treatment-experienced and HIV co-infected patients with chronic genotype-1 HCV. Deleobuvir, also known as BI 207127, is an investigational NS5B non-nucleoside polymerase inhibitor that has shown the potential to eliminate interferon from HCV treatment when combined in a regimen with faldaprevir and RBV. Phase 2 trials of this interferon-free regimen have been completed and Phase 3 HCVerso® trials investigating this regimen are now underway. As part of our long-term commitment to HCV, the company is exploring other combinations of investigational HCV compounds that work in complementary ways. The recent collaboration of Boehringer Ingelheim with Presidio Pharmaceuticals, Inc. for a Phase 2a clinical study investigating an interferon- and ribavirin-free, all-oral combination is part of the company's continued commitment to discover and develop innovative options for the treatment of HCV.

STARTVerso and HCVerso® are registered service marks of Boehringer Ingelheim International GmbH.

The Liver Meeting® is a registered trademark of the American Association for the Study of Liver Diseases (AASLD).

Hepatitis C is a blood-born infectious disease and a leading cause of chronic liver disease, transplant and failure that affects as many as 150 million people globally. In the United States, an estimated 4.1 million Americans have been infected with HCV, of which approximately 3.2 million have chronic HCV infection. Since 1999 there has been a significant increase in deaths due to chronic HCV, which accounts for 10,000-12,000 deaths in the United States per year.

About Boehringer Ingelheim 
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member o
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials
2. Shield Therapeutics Completes Recruitment to Pivotal Phase 3 Programme for Treatment of Iron Deficiency
3. CSL Behring Doses First Patient in Part 3 of Global Phase I/III Pivotal Study of rVIII-SingleChain (Recombinant Single-Chain Factor VIII) for Treatment of Hemophilia A
4. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
5. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
6. Relievant Medsystems Achieves Completion of Interim Safety Data Analysis of Intracept in SMART Pivotal Study and Expands Senior Leadership Team
7. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
8. Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
9. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
10. First U.S. Patients Treated in PneumRx RENEW Pivotal Study for Treatment of Severe Emphysema
11. ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 Regen BioPharma, Inc. (OTCBB: ... a novel means of delivering its patented (US ... liver tumors utilizing a clinically approved formulation as ... hurdles with gene silencing therapeutics in which the ... the whole body.  By utilizing a local delivery ...
(Date:8/31/2015)... 2015 BioLight Life ... ("BioLight" or the "Company"), a firm that invests ... and cancer diagnostics, today announced that its cancer ... several new genetic markers with high potential to ... with bisphosphonate drugs and was able to repeat ...
(Date:8/31/2015)... 31, 2015  AMRI (NASDAQ: AMRI ) ... collaboration focused on the development, manufacture and marketing ... ("APIs"). The collaboration combines Saneca,s strength in extracting ... developing and manufacturing controlled substance APIs with AMRI,s ... processes into these facilities. The collaboration will also ...
Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 2BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 3BioLight Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ 4AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 2AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 3AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical Ingredients 4
... April 28, 2011 There,s a sea change sweeping across the ... do they need to carry bottles of liquid and slow-acting pills ... a car, plane or when watching a 3-D movie. ... in the battle against motion-sickness, allowing people to easily avoid nausea ...
... (NYSE: CVS ) today announced it expects ... business of Universal American on Friday, April 29, 2011. ... shareholders cash consideration of $1.25 billion plus the excess ... Part D business, less Universal American,s outstanding trust preferred ...
Cached Medicine Technology:Zentrip Offers a 'Sea Change' in Stopping the Distress from Motion Sickness 2CVS Caremark to Complete Acquisition of Universal American's Medicare Part D Business 2CVS Caremark to Complete Acquisition of Universal American's Medicare Part D Business 3
(Date:8/31/2015)... ... 31, 2015 , ... CareSource, a nonprofit Ohio-based health plan, ... capacity, Michael will provide strategic leadership for CareSource’s marketing, branding, corporate communications and ... have contributed to the company’s rapid growth. As the CareSource business model expands ...
(Date:8/31/2015)... BAY PINES, FL (PRWEB) , ... August 31, 2015 , ... ... accessible, high quality healthcare to Veterans residing across southwest Florida by hiring more doctors ... added to the list of expanded services. , In early July, Dr. Anthony Jabre ...
(Date:8/31/2015)... ... September 01, 2015 , ... ... for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy ”. , ... Traumatic brain injury has been largely untreatable - with mostly palliative treatments only ...
(Date:8/31/2015)... ... , ... Since 1946, the doctors and staff at Clifton Dental Associates have ... arrives at the office, the staff will make them feel welcome and comfortable. ... create a complete dental treatment plan that is unique to each smile! NJ ...
(Date:8/31/2015)... ... August 31, 2015 , ... With the FCPX LUT Soft pack from Pixel Film Studios, editors ... Table that contains a mathematical formula for modifying an image. The LUT changes every pixel's ... CUBE LUT files. , FCPX LUT Soft requires Final Cut Pro X 10.2 or ...
Breaking Medicine News(10 mins):Health News:CareSource Names Vice President, Marketing and Corporate Communications 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 2Health News:Neurosurgeon Selected to Lead Growing Spine Care Program 3Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Dentists Presents, Clifton Dental Associates! 2Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2
... 2011 The children most likely to walk or cycle ... and in an economically disadvantaged home, according to survey results ... Roman Pabayo of the University of Montreal Hospital Research Centre ... study is unique in that it follows the same group ...
... SATURDAY, July 2 (HealthDay News) -- Staying hydrated is critical ... have different hydration needs, so you need to assess your ... of Tennessee at Chattanooga. "Sweat rate is very simple ... as possible; exercise for half an hour and don,t drink ...
... News) -- Nausea and vomiting after waking from general anesthesia ... from 122 patients with severe postoperative nausea and vomiting (PONV) ... initially identified 41 genetic targets (single nucleotide polymorphisms -- SNPs) ... them to at least one SNP that was common to ...
... contain baked milk into the diets of children who have ... according to a study conducted at Mount Sinai School of ... the May 23 issue of the Journal of Allergy ... 2 to 17 years old, who were diagnosed with milk ...
... 1 (HealthDay News) -- Increasing daily soluble fiber intake may ... other substances linked to a host of chronic diseases, according ... found just under the skin, visceral fat is located deep ... Researchers at Wake Forest Baptist Medical Center found the way ...
... 1, 2011 Surgery and all its implications can be ... dread sometimes disfiguring scars. Now a UT Southwestern Medical ... that makes scarring virtually invisible yet is just as effective ... with minimally invasive surgery, leave the child with up to ...
Cached Medicine News:Health News:Urban children are healthier commuters than rural teens 2Health News:How to Stay Hydrated in Hot Weather 2Health News:Foods with baked milk may help build tolerance in children with dairy allergies 2Health News:Soluble Fiber Appears Key to Trimming 'Bad Fat' 2Health News:UT Southwestern pediatric urologist develops procedure to eliminate scarring in kidney surgeries 2
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTC/1Q chairs are recommended for ... clean room, static control, health care ...
... chairs with concave seats and ... • Select options like seats, ... glides. • BTT/1P chairs are ... industry, education, laboratory, clean room, ...
... concave seats and standard-sized backrests with ... seats, backrests, armrests, and casters and ... for the following environments: industry, education, ... care and office. • With tubular ...
Medicine Products: